E. Schönbrunn

7.1k total citations
96 papers, 5.4k citations indexed

About

E. Schönbrunn is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, E. Schönbrunn has authored 96 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Biology, 24 papers in Oncology and 19 papers in Hematology. Recurrent topics in E. Schönbrunn's work include Protein Degradation and Inhibitors (25 papers), Multiple Myeloma Research and Treatments (18 papers) and Cancer-related Molecular Pathways (18 papers). E. Schönbrunn is often cited by papers focused on Protein Degradation and Inhibitors (25 papers), Multiple Myeloma Research and Treatments (18 papers) and Cancer-related Molecular Pathways (18 papers). E. Schönbrunn collaborates with scholars based in United States, Germany and Switzerland. E. Schönbrunn's co-authors include Susanne Eschenburg, Eckhard Mandelkow�, Alexander Marx, Huijong Han, Mathew P. Martin, Nikolaus Amrhein, T. Funke, Wolfgang Kabsch, S.H. Olesen and Gunda I. Georg and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

E. Schönbrunn

95 papers receiving 5.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Schönbrunn United States 42 3.8k 1.0k 802 736 601 96 5.4k
Fritz K. Winkler Switzerland 35 3.2k 0.8× 405 0.4× 837 1.0× 402 0.5× 289 0.5× 60 4.9k
Masoud Vedadi Canada 49 7.9k 2.1× 337 0.3× 499 0.6× 968 1.3× 558 0.9× 141 9.7k
Pavol Skubák Netherlands 9 5.3k 1.4× 489 0.5× 561 0.7× 648 0.9× 439 0.7× 18 7.4k
Richard N. Armstrong United States 45 5.7k 1.5× 288 0.3× 188 0.2× 497 0.7× 594 1.0× 142 7.4k
Joris Messens Belgium 42 3.7k 1.0× 888 0.9× 472 0.6× 189 0.3× 360 0.6× 130 5.5k
Gilles Labesse France 43 3.1k 0.8× 484 0.5× 524 0.7× 298 0.4× 270 0.4× 127 4.9k
Joseph D. Schrag Canada 40 5.8k 1.5× 413 0.4× 736 0.9× 349 0.5× 600 1.0× 71 7.4k
Michail N. Isupov United Kingdom 34 3.7k 1.0× 373 0.4× 381 0.5× 315 0.4× 402 0.7× 116 5.2k
Albert M. Berghuis Canada 39 4.5k 1.2× 223 0.2× 886 1.1× 396 0.5× 480 0.8× 116 5.9k
Daniel Lim United States 23 3.0k 0.8× 314 0.3× 963 1.2× 429 0.6× 245 0.4× 38 4.4k

Countries citing papers authored by E. Schönbrunn

Since Specialization
Citations

This map shows the geographic impact of E. Schönbrunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Schönbrunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Schönbrunn more than expected).

Fields of papers citing papers by E. Schönbrunn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Schönbrunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Schönbrunn. The network helps show where E. Schönbrunn may publish in the future.

Co-authorship network of co-authors of E. Schönbrunn

This figure shows the co-authorship network connecting the top 25 collaborators of E. Schönbrunn. A scholar is included among the top collaborators of E. Schönbrunn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Schönbrunn. E. Schönbrunn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liang, T. Jake, Jonathan Solberg, Rui Shi, et al.. (2025). Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors. European Journal of Medicinal Chemistry. 290. 117504–117504.
2.
Schmitz, Maximilian, Solomon Tadesse, Vinayak Palve, et al.. (2024). Discovery and design of molecular glue enhancers of CDK12–DDB1 interactions for targeted degradation of cyclin K. RSC Chemical Biology. 6(1). 36–55. 3 indexed citations
3.
Cuellar, Rebecca A. D., Sanny S.W. Chung, H.L.S. Wong, et al.. (2023). Strategies for developing retinoic acid receptor alpha-selective antagonists as novel agents for male contraception. European Journal of Medicinal Chemistry. 261. 115821–115821. 7 indexed citations
4.
Bayle, Simon, et al.. (2023). Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties. European Journal of Medicinal Chemistry. 266. 116101–116101. 3 indexed citations
5.
Faber, Erik B., Nan Wang, An‐Suei Yang, et al.. (2023). Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding. Nature Communications. 14(1). 27 indexed citations
6.
Berndt, Norbert, et al.. (2022). Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. Journal of Medicinal Chemistry. 65(15). 10441–10458. 12 indexed citations
7.
Yang, Leixiang, Lihong Chen, Junhao Lu, et al.. (2022). Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain. Journal of Medicinal Chemistry. 65(5). 4182–4200. 17 indexed citations
8.
Sigua, Logan H., Tingjian Wang, Deyao Li, et al.. (2021). Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors. Journal of Medicinal Chemistry. 64(9). 5787–5801. 22 indexed citations
9.
Hong, Kwon Ho, et al.. (2021). Tetrahydroindazole inhibitors of CDK2/cyclin complexes. European Journal of Medicinal Chemistry. 214. 113232–113232. 6 indexed citations
10.
Huang, Qingling, Lihong Chen, E. Schönbrunn, & Jiandong Chen. (2020). MDMX inhibits casein kinase 1α activity and stimulates Wnt signaling. The EMBO Journal. 39(14). e104410–e104410. 10 indexed citations
11.
Hanna, Carol, Shan Yao, E. Schönbrunn, et al.. (2019). Identification and Screening of Selective WEE2 Inhibitors to Develop Non‐Hormonal Contraceptives that Specifically Target Meiosis. ChemistrySelect. 4(45). 13363–13369. 7 indexed citations
12.
Mishra, Neeraj K., Huarui Cui, John C. Widen, et al.. (2018). Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase–Bromodomain Inhibitor. Journal of Medicinal Chemistry. 61(20). 9316–9334. 51 indexed citations
13.
Ember, S.W., Que T. Lambert, Norbert Berndt, et al.. (2017). Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. Molecular Cancer Therapeutics. 16(6). 1054–1067. 41 indexed citations
14.
Gupta, Vijayalaxmi, J. Zhu, Joseph S. Tash, et al.. (2017). Structure–Activity Studies of N‐Butyl‐1‐deoxynojirimycin (NB‐DNJ) Analogues: Discovery of Potent and Selective Aminocyclopentitol Inhibitors of GBA1 and GBA2. ChemMedChem. 12(23). 1977–1984. 13 indexed citations
15.
Allen, Bryce K., Saurabh Mehta, S.W. Ember, et al.. (2017). Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations. ACS Omega. 2(8). 4760–4771. 28 indexed citations
16.
Allen, Bryce K., et al.. (2015). Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. Scientific Reports. 5(1). 16924–16924. 48 indexed citations
17.
Mishra, Neeraj K., Andrew K. Urick, S.W. Ember, E. Schönbrunn, & William C. K. Pomerantz. (2014). Fluorinated Aromatic Amino Acids Are Sensitive 19F NMR Probes for Bromodomain-Ligand Interactions. ACS Chemical Biology. 9(12). 2755–2760. 79 indexed citations
18.
Pireddu, Roberta, Ying Sun, Nan Sun, et al.. (2012). RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer. Cancer Research. 72(19). 5025–5034. 123 indexed citations
19.
Eschenburg, Susanne, et al.. (2005). A Novel Inhibitor That Suspends the Induced Fit Mechanism of UDP-N-acetylglucosamine Enolpyruvyl Transferase (MurA). Journal of Biological Chemistry. 280(14). 14070–14075. 55 indexed citations
20.
Kozielski, Frank, Stefan Sack, Alexander Marx, et al.. (1997). The Crystal Structure of Dimeric Kinesin and Implications for Microtubule-Dependent Motility. Cell. 91(7). 985–994. 330 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fritz K. Winkler Breakdown of academic impact, for papers by Masoud Vedadi Breakdown of academic impact, for papers by Pavol Skubák Breakdown of academic impact, for papers by Richard N. Armstrong Breakdown of academic impact, for papers by Joris Messens Breakdown of academic impact, for papers by Gilles Labesse Breakdown of academic impact, for papers by Joseph D. Schrag Breakdown of academic impact, for papers by Michail N. Isupov Breakdown of academic impact, for papers by Albert M. Berghuis Breakdown of academic impact, for papers by Daniel Lim
Rankless by CCL
2026